Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 391-399, July 2009

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

  • Guru Sonpavde, M.D.

      Affiliations

    • Texas Oncology, P.A. and U.S. Oncology Research, Houston, TX 77030, USA
    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • Section of Medical Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +281-332-7505; fax: +281-332-8429
    • Received research funding from Pfizer, Inc. toward this research project and is on the Speakers' Bureau for Pfizer.
    • ,
  • Weiguo Jian, M.D.

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Hao Liu, M.D.

      Affiliations

    • Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Meng-Fen Wu, M.S.

      Affiliations

    • Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    • ,
  • Steven S. Shen, M.D., Ph.D.

      Affiliations

    • Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    • ,
  • Seth P. Lerner, M.D.

      Affiliations

    • Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    • Received research funding from Pfizer, Inc. toward this research project.

Received 22 January 2008; received in revised form 3 March 2008; accepted 9 March 2008. published online 05 June 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1078-1439(08)00069-0

doi:10.1016/j.urolonc.2008.03.017

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 4 , Pages 391-399, July 2009

Article Tools

* Image Usage & Resolution